CONCLUSIONS: Patients with VHL-CNS-Hb had a substantial, long-term clinical burden that included treatment for multiple VHL manifestations—reflecting the multi-organ nature of the disease—frequent pain management drug use, and high levels of healthcare use for disease monitoring and specialist visits. The gene discussed is GSTM1; the disease is von Hippel-Lindau disease.